Parabilis Medicines
MA - CambridgeBiotechnology
Focus: Parabilis Medicines is a Cambridge-based biotechnology company pioneering cell-penetrating miniproteins for oncology, currently advancing a Phase 1/2 program. The company recently completed a $770.5M IPO in June 2026, establishing public-market validation for its novel platform technology.
Profile data last refreshed 17h ago · AI intelligence enriched 2mo ago
Total Funding
$305M
Open Jobs
19+5 this month
Growing — net +5 jobs in 30d
7 jobs added vs 2 removed. Steady team buildout.
Should You Work at Parabilis Medicines?
AI assessmentParabilis is a high-risk, high-reward opportunity for scientists and operators who thrive in capital-efficient startup environments and want equity upside tied to a novel platform's clinical validation.
Why Work Here
- IPO-stage inflection point (June 2026) means expanding team, budget, and career acceleration potential in an emerging modality with limited competition.
Data completeness
4/9 — Basic
Company HealthSolid
Pipeline
Early-stage
1 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
FOG-001
CancerClinical Trials (1)
NCT05919264FOG-001 in Locally Advanced or Metastatic Solid Tumors
Phase 1/2Help build intelligence for Parabilis Medicines
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.